Arch Therapeutics Announces Presentations on AC5 Advanced Wound System at the 2020 Symposium on Advanced Wound Care (SAWC) Fall
Arch Therapeutics (OTCQB:ARTH) announced its AC5 Advanced Wound System's potential through three clinical case reports and two animal studies, which will be presented at the 2020 Symposium on Advanced Wound Care from November 4-6, 2020. The AC5 Advanced Wound System recently received FDA marketing authorization, and a comparable product received a CE mark in Europe. Clinical reports focus on managing complex wounds, asserting the system's efficacy during the ongoing pandemic.
- FDA marketing authorization received for AC5 Advanced Wound System.
- Presentation of clinical case reports highlights the product's effectiveness in managing complex wounds.
- None.
A series of clinical case reports and animal studies support the broad potential of AC5 Advanced Wound System in a range of complicated acute and chronic wounds
FRAMINGHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that three clinical case reports and two animal studies of AC5® Advanced Wound System will be described in poster presentations at the upcoming 2020 Symposium on Advanced Wound Care (SAWC) Fall Virtual. The event will take place from November 4-6, 2020.
AC5 Advanced Wound System recently received marketing authorization by the US Food and Drug Administration. A comparable product, AC5 Topical Hemostat, recently received a CE mark in Europe.
The following clinical case reports, which examine the use of the product in patients by surgeons, will be presented:
| • | Enabling Aggressive Surgical Debridement and Healing in a 10-year-old Decubitus Ulcer with a Novel Self-Assembling Peptide-based Advanced Wound Dressing (poster #CS-022) | ||
| Ο | Randall Wolcott, MD (Wound & Burn Specialist, Southwest Regional Wound Care Center) | ||
| Ο | Terrence Norchi, MD and Daniel Wadsworth (Arch Therapeutics) | ||
| • | Healing of a Chronic Refractory Burn Wound with a Novel Self-Assembling Peptide-based Advanced Wound Dressing (poster #CS-026) | ||
| Ο | Randall Wolcott, MD (Wound & Burn Specialist, Southwest Regional Wound Care Center) | ||
| Ο | Kalpana Kamath, PhD (Arch Therapeutics) | ||
| • | Healing of a Complex Surgical Wound using a Novel Self-Assembling Peptide-based Advanced Wound Dressing (poster #CS-027) | ||
| Ο | Dan Kapp, MD (Chief of Surgery, Palm Beach Gardens Medical Center) | ||
| Ο | Terrence Norchi, MD (Arch Therapeutics) | ||
| The following animal studies will be presented: | |||
| • | Effects of a Self-Assembling Peptide on Second Degree Burn Progression and Healing in a Porcine Model | ||
| Ο | Alexander Higa, Joel Gil, Michael Solis, Colin Simms and Stephen C. Davis (Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida) | ||
| • | Effects of a Self-Assembling Peptide on Full-Thickness Wound Healing in a Porcine Model | ||
| Ο | Joel Gil, Michael Solis, Alexander Higa, Colin Simms, Jie Li and Stephen Davis (Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida) | ||
Terrence W. Norchi, MD, President and CEO of Arch said, “Observations by surgeons regarding the utility of AC5 Advanced Wound System in helping manage complicated wounds in challenging settings have been incredibly instructive, particularly now as the burden of chronic wounds during the ongoing pandemic is more apparent; the necessity of considering their care to be a true emergency is clear. These initial clinical case reports, which assessed real time use of AC5 Advanced Wound System in patients as well as the preclinical animal studies that are being presented, are important contributors to our understanding of the potential for the product and its underlying technology.”
Registration for the Symposium can be found at the following link: https://www.sawcfall.com/rates
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's products authorized for commercial marketing are AC5® Advanced Wound System and AC5® Topical Hemostat.1 Arch's development stage product candidates include AC5-V®, AC5-GTM and AC5® Surgical Hemostat, among others.2
About The Symposium on Advanced Wound Care
The Symposium on Advanced Wound Care features exciting new cutting-edge topics led by the most dynamic and influential educators in wound healing to further move the wound care community forward, and create a dynamic and unified voice to support our shared mission – improving patient care.
About HMP
HMP is the force behind Healthcare Made Practical – and is a multichannel leader in health care events and education, with a mission to improve patient care. The company produces accredited medical education events and clinically relevant, evidence-based content for the global health care community across a range of therapeutic areas. Its brands include Consultant360, the year-round, award-winning platform relied upon by primary care providers and other specialists; Psych Congress, the largest independent mental health meeting in the U.S.; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
Source: Arch Therapeutics, Inc.
Contact
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
or
Richard Davis
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2308
Email: rdavis@archtherapeutics.com
Website: www.archtherapeutics.com
1. AC5 Advanced Wound System and AC5 Topical Hemostat have received regulatory authorization for commercial marketing as medical devices in the USA and EU, respectively.
2. AC5-V, AC5-G and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
AC5 and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.
FAQ
What recent developments has Arch Therapeutics made regarding AC5 Advanced Wound System?
When will the Symposium on Advanced Wound Care take place?
What is the significance of the recent clinical case reports for Arch Therapeutics?
What does the CE mark for the AC5 Topical Hemostat signify?
